A Lyme vaccine's second yearly booster held up in a phase 2 trial

There is no licensed vaccine against Lyme disease, the most common tick-borne illness in the temperate Northern Hemisphere [s1]. The leading candidate, VLA15, is still in trials, and a new report in Nature Communications adds a specific piece to the puzzle: whether a second yearly booster keeps the immune response going after the first one fades [s1]. The short answer is that it does, at least by the antibody measures the trial tracked, and without the kind of safety problem that ended the last Lyme vaccine to reach the market [s1].

What VLA15 is

VLA15 targets outer surface protein A (OspA), a protein on the surface of Borrelia burgdorferi, the bacterium that causes Lyme disease. The vaccine contains six OspA serotypes, chosen to cover the strains that circulate in North America and Europe [s1]. The design is deliberately reminiscent of LYMErix, the OspA vaccine licensed in the United States in 1998 and withdrawn in 2002 amid unproven fears — never borne out by evidence — that it caused arthritis. VLA15's developers redesigned the antigen to remove the portion that had drawn that suspicion, and the current trial programme is partly about demonstrating a clean safety record over repeated dosing.

What the trial did

This was a randomised, observer-blinded, placebo-controlled phase 2 trial in participants aged 5 to 65 years, run in Lyme-endemic areas [s1]. Participants were randomised 1:1:1 to one of three schedules: VLA15 at Months 0, 2 and 6; VLA15 at Months 0 and 6 with placebo at Month 2; or placebo at every visit [s1]. Everyone who had received VLA15 then got yearly booster doses at Month 18 and Month 30, while the placebo group received placebo boosters [s1]. The new paper reports what happened from Month 19 through Month 31 — the window covering that second booster [s1]. In the booster phase, 449 participants received the Month 18 booster and 392 went on to receive the Month 30 booster [s1].

The distinction being tested here matters. Earlier reports covered the primary course and the first booster; this analysis is specifically about whether a second annual booster still works after antibody levels have had another year to decline [s1]. That is the real-world question, because Lyme risk recurs every tick season and any vaccine would need repeated boosting to stay useful.

What it found

OspA-specific IgG antibody titres, measured by ELISA, declined between Months 19 and 30 in both VLA15 groups — the expected waning after the first booster [s1]. The Month 30 booster then triggered a strong anamnestic response, meaning the immune system remembered the antigen and mounted a rapid rebound across all six serotypes and all age groups, qualitatively similar to the response seen after the Month 18 booster [s1]. Measured as geometric mean fold rises from Month 7 to Month 31, the increases ranged from 2.8-fold (serotype 2, in the three-dose primary schedule) to 4.8-fold (serotype 1, in the two-dose primary schedule) [s1]. Both VLA15 groups stayed significantly above placebo throughout (all P<0.0001) [s1].

It is worth being precise about what this shows. These are immunogenicity results — antibody levels, not disease prevented. The trial was not designed or sized to show that VLA15 stops people getting Lyme disease; that is the job of the separate phase 3 efficacy trial. A booster that restores antibodies is a necessary step, but antibody titres are a surrogate, and a surrogate is only as good as its link to real protection. The plain-language summary accompanying the programme frames the finding the same modest way: the data support a schedule of primary vaccination followed by yearly boosting to optimise potential protection [s2].

Safety

Reactogenicity rose with boosting, as it often does. Solicited local reactions after the Month 30 booster were more frequent in the VLA15 M0-2-6-18-30 group (83.3%) and the M0-6-18-30 group (78.9%) than in the placebo group (15.0%; both P<0.0001), with injection-site pain and tenderness the most common [s1]. That is a sore arm, not a red flag — and it is the kind of predictable local reaction that comes with an active vaccine.

The more important numbers point the other way. Serious adverse events were reported by 2.9% of all VLA15 recipients versus 5.3% of placebo recipients (overall P=0.0094), and medically attended adverse events by 13.4% versus 19.9% (P=0.0322) [s1]. In other words, serious and medically attended events were less common in the vaccinated groups — consistent with chance imbalance rather than any vaccine harm, and nothing resembling the arthritis signal that dogged the earlier product. No new safety concerns arose through Month 31 [s1].

What it means

For anyone who has watched a Lyme vaccine come and go before, the useful reading is cautious optimism. VLA15's second yearly booster does what a booster is supposed to do — it brings the antibodies back — and it does so with a tolerability profile that looks acceptable [s1]. What this trial cannot tell you is whether that translates into fewer cases of Lyme disease in the field; only the ongoing phase 3 efficacy trial can answer that. Anyone reading a headline that says a Lyme vaccine "works" should ask which endpoint is meant: this is strong immune-response data, not proof of protection [s1][s2].

Sources

• [s1] A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals. Nature Communications, 4 Aug 2026. https://doi.org/10.1038/s41467-026-75871-3
• [s2] Booster vaccination with an investigational Lyme disease vaccine in children, adolescents, and adults: a plain language summary. Expert Review of Vaccines, 27 Sep 2026. https://doi.org/10.1080/14760584.2026.2722004